Home
Categories
Ingredients
Research & Development
Manufacturing
Packaging
Active Nutrition
Cardiovascular
Digestion
Cognitive
Finance
Regulatory
Company News
Events
Directory
Search
Close search
Home
Company
GW Pharmaceuticals
GW Pharmaceuticals
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
From subscriptions to mushrooms: BCMPA members discuss the latest outsourcing trends in nutraceuticals
From single-serve sachets catering to the busy on-the-go market to specialised subscription models shaping direct-to-consumer interactions, the nutraceutical industry is...
The perfect pair: how vitamins K2 and D3 combine to support health and well-being
Hydrogen and oxygen, Yin and Yang, Batman and Robin; the world is full of iconic duos that combine to become more than the sum of their parts. One relatively unknown yet...
LifeinU BSCU1: embrace your health now and for the future
New biotics solutions are flooding the market to capitalise on the ever-changing immunity seeking consumer. However, one probiotic solution, LifeinU® BSCU1 from Gnosis by...
Macalat earns NEXTY award for chocolate mushroom mycelium technology
The organic brand has created a novel category in the chocolate industry: sweet dark chocolate
Mibelle Biochemistry has strengthened its beauty-from-within portfolio
PhytoCellTec Md Nu, a novel anti-aging solution, utilises the power of apple fruit cell culture extract to boost skin stem cell vitality and enhance skin density, elasticity,...
Upcoming event
Vitafoods Europe
14–16 May 2024 | Exhibition | Palexpo, Geneva
See all
Related Content
Finance
GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
The British biopharmaceutical company has released Q4 and 2019 financial year results
Manufacturing
Momentum in the US cannabidiol market gains retailers' attention
Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory
First prescription CBD from GW Pharma has restriction lowered
The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Ingredients
Marijuana derivative reduces seizures in children and young adults with treatment-resistant epilepsy
New open-label trial of prescription cannabidiol shows overall safety and efficacy
Subscribe now